NCT03070392 2026-03-17Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaImmunocore LtdPhase 2 Completed378 enrolled 15 charts 1 FDA
NCT05907954 2026-03-16(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaIDEAYA BiosciencesPhase 2 Active not recruiting160 enrolled
NCT05199584 2026-03-05A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsEndeavor Biomedicines, Inc.Phase 2 Completed20 enrolled
NCT04417530 2025-03-03Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal MelanomaAura BiosciencesPhase 2 Completed22 enrolled
NCT00084656 2022-04-14Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV MelanomaBristol-Myers SquibbPhase 2 Completed77 enrolled 13 charts
NCT01328106 2017-12-12Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal MelanomaGlaxoSmithKlinePhase 2 Withdrawn
NCT00096083 2013-10-23Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver CancerDelcath Systems Inc.Phase 2 Completed56 enrolled